Following treatment, these aged-treated mice quickly developed tumours within days, which highlights the strong tumour-promoting effect of BRAFi in Hras mutant skin and models the development of cSCC in melanoma patients with Hras mutations (Fig. 1f). The gene discussed is HRAS; the disease is melanoma.